Fosun Pharma has reported its interim results for the first half of 2026, highlighting a revenue increase of 4.75% year-on-year, reaching RMB 20.442 billion, and a notable profit growth of 19.09%. The company’s revenue from innovative drugs rose by 13.84%, now making up over a third of its pharmaceutical segment revenue. Fosun Pharma remains focused on oncology, immunology, and neurodegenerative diseases, significantly boosting its R&D investment by 25.66% to RMB 3.247 billion. During this period, 20 drug indications were approved, further establishing its global competitive position, especially with products like Han Si Zhuang (Serplulimab) and Han Bei You (Pertuzumab). Strategic partnerships for drug development and commercialization were also reinforced, demonstrating Fosun’s commitment to advancing innovation and globalization within the pharmaceutical industry.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.tradingview.com/news/prnewswire:9f02fb674e11a:0-fosun-pharma-announces-2026-interim-results/
